PROMET-BR - Molecular Profiling of Metastatic Prostate Cancer: a Brazilian Cohort

Sponsor
AstraZeneca
Study ID
NCT07560215
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Metastatic Prostate Cancer

Eligibility Criteria

Sex
MALE
Age
18 Years - 99 Years
Healthy Volunteers
Not accepted

Interventions

  • Archived FFPE tissue biopsy and/or newly acquired liquid biopsy for molecular profiling. — DIAGNOSTIC_TEST
    The exposure/intervention under investigation is the use of archived FFPE tissue biopsy and/or newly acquired liquid biopsy for molecular profiling.

Study Details

PROMET-BR is an observational, retrospective and prospective real-world study in Brazil designed to characterize clinically relevant molecular alterations in metastatic prostate cancer and explore their association with patient outcomes in routine practice. The study will be conducted within Oncoclínicas \& Co and will integrate centralized biomarker testing performed at OC Precision Medicine laboratories with retrospectively assembled clinical data from electronic health records (EHRs) from participating sites. Treatments are not assigned by the protocol; patients receive standard-of-care palliative systemic therapy at the discretion of their treating physicians.

Key Dates

First listed
May 1, 2026
Start date
Apr 30, 2026
Status verified
Apr 2026
Primary completion
Mar 31, 2027
Completion
Mar 31, 2027

Study Design

Enrollment
100 participants (estimated)

Arms

  • Arm: metastatic prostate cancer receiving palliative systemic therapy at Oncoclínicas & Co
    metastatic prostate cancer receiving palliative systemic therapy at Oncoclínicas \& Co

Primary Outcome Measure

prevalence of HRR mutations in tissue and/or liquid biopsy samples [ Time Frame: april 2026 to april 2027 ]

Central Contacts

Related Studies